Article Text

Download PDFPDF

Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP

Statistics from

 Q How does pretreatment systolic blood pressure (SBP) affect the efficacy and safety of carvedilol in patients with severe chronic heart failure (HF)?

Clinical impact ratings IM/Ambulatory care ★★★★★★★ Internal medicine ★★★★★★★ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial (Carvedilol Prospective Randomized Cumulative Survival [COPERNICUS] study).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients and outcome assessors).*

Embedded ImageFollow up period:

mean 10.4 months at early termination of study.

Embedded ImageSetting:

334 centres in 21 countries.

Embedded ImagePatients:

2289 patients (mean age 63 y, 80% men) with severe chronic HF because of ischaemic or non-ischaemic cardiomyopathy; ⩾2 months of dyspnoea or fatigue at rest or on minimal exertion; left ventricular ejection fraction <25%; and SBP >85 mm Hg. Exclusion criteria: correctable cause of HF; heart transplant; severe primary pulmonary, renal, or hepatic disease; contraindications to β blockers; major cardiac event within 2 months; use of α adrenergic blockers, calcium channel blockers, or class I antiarrhythmic drugs within 4 weeks; heart rate <68 beats/minute, serum creatinine concentration >2.8 mg/dl or an increase …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.